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Abstract
Background: In patients with chronic ischemic heart disease (IHD), the presence and extent of spontaneously visible
coronary collaterals are powerful determinants of clinical outcome. There is marked heterogeneity in the recruitment of
coronary collaterals amongst patients with similar degrees of coronary artery stenoses, but the biological basis of this
heterogeneity is not known. Chemokines are potent mediators of vascular remodeling in diverse biological settings. Their
role in coronary collateralization has not been investigated. We sought to determine whether plasma levels of angiogenic
and angiostatic chemokines are associated with of the presence and extent of coronary collaterals in patients with chronic
IHD.
Methodology/Principal Findings: We measured plasma concentrations of angiogenic and angiostatic chemokine ligands in
156 consecutive subjects undergoing coronary angiography with at least one $90% coronary stenosis and determined the
presence and extent of spontaneously visible coronary collaterals using the Rentrop scoring system. Eighty-eight subjects
(56%) had evidence of coronary collaterals. In a multivariable regression model, the concentration of the angiogenic ligands
CXCL5, CXCL8 and CXCL12, hyperlipidemia, and an occluded artery were associated with the presence of collaterals;
conversely, the concentration of the angiostatic ligand CXCL11, interferon-c, hypertension and diabetes were associated
with the absence of collaterals (ROC area 0.91). When analyzed according to extent of collateralization, higher Rentrop
scores were significantly associated with increased concentration of the angiogenic ligand CXCL1 (p,0.0001), and
decreased concentrations of angiostatic ligands CXCL9 (p,0.0001), CXCL10 (p=0.002), and CXCL11 (p=0.0002), and
interferon-c (p=0.0004).
Conclusions/Significance: Plasma chemokine concentrations are associated with the presence and extent of spontaneously
visible coronary artery collaterals and may be mechanistically involved in their recruitment.
Citation: Keeley EC, Moorman JR, Liu L, Gimple LW, Lipson LC, et al. (2011) Plasma Chemokine Levels Are Associated with the Presence and Extent of
Angiographic Coronary Collaterals in Chronic Ischemic Heart Disease. PLoS ONE 6(6): e21174. doi:10.1371/journal.pone.0021174
Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands
Received February 7, 2011; Accepted May 21, 2011; Published June 22, 2011
Copyright:  2011 Keeley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (HL97074 to ECK, HL73848 to BM, and CA87879, HL66027 and HL98526 to RMS). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Keeley@Virginia.edu
Introduction
Chronic ischemic heart disease (IHD), the most common
clinical manifestation of coronary artery disease, results in
progressive myocardial ischemia due to gradual narrowing of the
coronary arterial lumina and is manifested clinically as medically
refractory angina, ischemic cardiomyopathy, congestive heart
failure, and cardiac arrhythmias [1]. A major compensatory
mechanism in patients with chronic IHD is the recruitment of
coronary collaterals, a form of vascular remodeling that can be
quantified angiographically. Presence of spontaneously visible
coronary collaterals is associated with better outcomes in a broad
spectrum of patients with varying degrees of IHD burden [2],
including patients with acute myocardial infarction [3,4,5,6,7,8],
and patients with chronic IHD undergoing percutaneous [9,10]
and surgical [11,12,13] coronary revascularization. Recruitable
coronary collaterals have also been assessed in patients with
chronic IHD and are similarly associated with improved clinical
outcomes [14]. The assessment of recruitable collaterals in the
absence of chronic coronary occlusion, however, requires balloon
occlusion of the collateral-receiving artery with simultaneous
angiography of the collateral-supplying artery [15]. Thus, the
physiological relevance of recruitable collaterals is limited to the
context of complete coronary obstructions, whereas the presence
of spontaneous collaterals can be seen in situations where lesions
are flow-limiting but not necessarily completely occlusive.
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artery stenosis exhibit marked variability in the presence of
spontaneously visible collaterals, but the biological basis of this
heterogeneity is not known [16]. Studies of the mechanisms
underlying the recruitment of coronary collaterals have, in large
part, concentrated on the potential contribution of growth factors
including vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) with inconsistent results
[17,18,19,20,21]. Thus, the mechanisms that contribute to the
successful recruitment of coronary collaterals remain obscure.
Chemokines are a superfamily of structurally homologous
cytokines that were originally described for their role in mediating
leukocyte recruitment, but were subsequently found to be
important regulators of vascular remodeling in diverse biological
settings [22]. Chemokines are structurally defined by four
conserved cysteine residues at their amino terminus and are
classified into CC, CXC, C, and CX3C families based on the
sequence of aminoacids in relation to the first 2 cysteine residues.
The CXC ligands are further subdivided on the basis of presence
or absence of a glutamic acid-leucine-arginine sequence (Glu-Leu-
Arg or ‘ELR’ motif) immediately adjacent to the CXC motif [23].
The presence of this ELR motif is functionally important, since the
ELR-containing CXC chemokine ligands (CXCL1, CXCL2,
CXCL3, CXCL5, CXCL6, and CXCL8) are potent promoters
of vascular remodeling, whereas a subset of the non-ELR CXC
chemokine ligands (CXCL4, CXCL9, CXCL10, CXCL11) are
potent inhibitors of angiogenesis [22,23]. The contribution of the
CXC chemokines to vascular remodeling of the myocardium in
chronic IHD has not been studied in detail. The aim of this study
was to test the hypothesis that in patients with chronic IHD, a
profile of circulating levels of CXC chemokines is associated with
the presence and extent of spontaneously visible coronary
collaterals. We found that chemokines play an important role in
both the presence and extent of coronary collaterals.
Methods
Objectives
To test the hypothesis that in patients with chronic IHD, a
profile of circulating levels of CXC chemokines is associated with
the presence and extent of spontaneously visible coronary
collaterals.
Participants
We prospectively collected demographic and angiographic data
from consecutive patients referred for coronary angiography at the
University of Virginia from October 2007 to August 2008. All
patients undergoing coronary angiography who were .21 years
old and able to provide informed consent were eligible for
enrollment. Exclusion criteria were: (1) patients with acute
coronary syndromes as defined by unstable or recent progression
or acceleration of symptoms and/or elevated blood troponin level;
(2) hematocrit ,30; (3) active inflammatory, infectious, or
malignant disease; (4) expected survival less than one year; and
(5) immunosuppressive therapy.
Description of Procedures
Following vascular access via the femoral, brachial or radial
artery and prior to coronary angiography or heparin administra-
tion, a 30ml peripheral blood sample was drawn from the side-arm
of the sheath, anticoagulated with sodium EDTA, immediately
placed on ice, and processed within 30 minutes of retrieval.
Platelet-free plasma was aliquoted and frozen at 280uC for
subsequent measurement of: CXCL1, CXCL3, CXCL5, CXCL8,
CXCL9, CXCL10, CXCL11, CXCL12, CCL2, VEGF and
bFGF, and interferon-gamma (IFN-c) by multiplex immunoassay
using the manufacturer’s instruction (Luminex, Bio-Rad, Bio-plex
200 system, Hercules, California; Procarta Cytokine Assay kit,
Panomics, Inc., Fremont, California).
Selective coronary angiography was performed in multiple
orthogonal views using standard techniques. Each angiogram was
initially read by the interventional cardiologist performing the
procedure (L.W.G., E.C.K., L.C.L., M.R., or A.M.T.), and the
presence, severity, and extent of coronary artery disease was
determined and entered into the cardiac catheterization labora-
tory computerized database. Angiograms reported to have at least
one major epicardial artery with a severe stenosis (defined as
$90% on visual estimation) were re-analyzed separately by 2
independent investigators (E.C.K. and L.L.) blinded to the clinical
data and cytokine levels for the presence and extent of coronary
collaterals. Since it has been previously shown that a severe flow-
limiting coronary artery lesion (defined as a diameter stenosis of
$90%) is a prerequisite for spontaneous collateral recruitment
[24], only patients in whom the angiogram documented at least
one lesion $90% were included. The presence and extent of
collaterals (if present) was determined according to the Rentrop
score [25]. If there was no evidence of a coronary collateral on the
angiogram, it was documented as Rentrop=0; if a collateral was
present, it was further graded according to the Rentrop score as
follows: Rentrop 1= filling of side branches of the artery without
visualization of epicardial segments; Rentrop 2= partial filling of
an epicardial artery; and Rentrop 3= complete filling of an
epicardial artery. Disparities in Rentrop scores in angiograms from
4 patients were refereed by a third blinded investigator (L.C.L.)
and data reflecting agreement from 2 of the 3 readers was used for
analyses. If the patient had more than one collateral, the collateral
with the highest Rentrop score was recorded and used for
statistical analyses. The reproducibility of the Rentrop score has
been previously described [26].
Ethics
This study was approved by the institutional review board of the
University of Virginia and all patients provided written informed
consent.
Statistical methods
The Fisher’s Exact test was used to compare categorical values
between patients with and without collaterals and the Wilcoxon
rank-sum test was used for continuous variables. Difference of
variables by Rentrop score were quantified using non-parametric
ANOVA analysis (Kruskal-Wallis test). All continuous variables
are reported as medians with interquartile ranges (IQR). A logistic
regression model using a stepwise backward-selection technique
was used to generate a multivariable model to determine the
factors associated with the presence or absence of collaterals. The
likelihood ratio test was used to test the significance of the
variables. Candidate variables included age, extent of coronary
artery disease, hypertension, diabetes, tobacco use, family history
of coronary artery disease, hyperlipidemia, history of angina,
history of peripheral vascular disease, history of congestive heart
failure, history of arrhythmias, history of stroke, prior myocardial
infarction, prior coronary artery bypass surgery, prior percutane-
ous coronary intervention, presence of an occluded artery and
HMG Co-A reductase inhibitor therapy. A stepwise backward
selection was performed using a threshold of p,0.10. All analyses
were performed with SAS 9.1 (SAS Institute, Cary, NC) or
MATLAB 7.9 (Natick, MA). A two-sided p value of ,0.05 was
considered statistically significant.
Chemokines and Coronary Collaterals
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We enrolled 275 consecutive patients of whom 156 (57%) had a
stenosis of $90% in at least one major epicardial coronary artery.
Clinical characteristics of the 156 patients are shown in Table 1.
Of the 156 patients, 88 (56%) had angiographic evidence of
collateralization. There were no significant differences in baseline
demographics (including race, data not shown), cardiac risk
factors, medical co-morbidities, and chronic medications between
patients with and without collaterals. Patients with collaterals had
a higher mean number of diseased vessels (2.4+/21.2 vs 1.9+/
21.0, p=0.009), and were more likely to have at least one
occluded coronary artery (85% vs 28%, p,0.0001), while patients
without collaterals were more likely to have disease of a single
coronary artery (43% vs 25%, p=0.025) (Table 1).
Determinants of the presence of collaterals
In order to determine whether specific angiogenic and
angiostatic factors and clinical characteristics were associated with
either the presence or absence of collaterals we first performed a
univariate analysis (Table 2). Subsequently, we performed a
multivariate analysis (Table 3) that included all the cytokines and
clinical characteristics listed in Table 2. In this best-fit model
(ROC area 0.91; sensitivity 80%, specificity 88% at an optimal
cutpoint), the factors associated with the presence of collaterals
were the chemokine profile consisting of CXCL5 (p=0.018),
CXCL8 (p=0.031), and CXCL12 (p=0.033), and the clinical
factors of hyperlipidemia (p=0.047), and the presence of an
occluded artery (p,0.0001). Factors associated with the absence of
collaterals were the cytokine profile consisting of CXCL11
(p=0.002) and IFN-c (p=0.021), and the clinical factors of
Table 1. Clinical characteristics of patients with $90% stenosis of at least one coronary artery.
with collaterals (n=88) no collaterals (n=68) p value
Demographic data
Men 66 (75%) 50 (74%) 0.855
Age (yrs, mean +/2 SD) 62611 62612 0.916
Cardiac risk factors
Diabetes 29 (33%) 31 (46%) 0.135
Hypertension 71 (81%) 62 (91%) 0.073
Hyperlipidemia 81 (92%) 58 (85%) 0.203
Current tobacco use 30 (34%) 25 (37%) 0.739
Peripheral vascular disease 27 (31%) 19 (28%) 0.727
Family history of coronary artery disease 43 (49%) 30 (44%) 0.628
Medical history
Prior stroke 8 (9%) 10 (15%) 0.318
Prior angina pectoris 50 (57%) 41 (60%) 0.744
Congestive heart failure 9 (10%) 6 (9%) 1.000
Prior myocardial infarction 40 (45%) 24 (35%) 0.251
History of cardiac arrhythmias 8 (9%) 7 (10%) 0.792
Prior coronary artery bypass surgery 23 (26%) 15 (22%) 0.579
Prior percutaneous coronary intervention 27 (31%) 26 (38%) 0.310
Chronic medications
Beta-blocker 64 (73%) 53 (78%) 0.576
Angiotensin-converting enzyme inhibitor 44 (50%) 37 (54%) 0.746
Aspirin 79 (90%) 63 (93%) 1.000
Insulin 12 (14%) 17 (25%) 0.098
Oral hypoglycemic 11 (13%) 7 (10%) 0.802
Calcium channel-blocker 17 (19%) 9 (13%) 0.288
Clopidogrel 20 (23%) 15 (22%) 0.849
HMG coA-reductase inhibitor 68 (77%) 52 (76%) 0.693
Extent of coronary artery disease
Number of diseased vessels 2.4+/21.2 1.9+/21.0 0.009
1-vessel disease 22 (25%) 29 (43%) 0.025
2-vessel disease 27 (31%) 19 (28%) 0.727
3-vessel disease 26 (29%) 17 (25%) 0.590
.3 vessel disease 13 (15%) 3 (4%) 0.060
Presence of any occluded artery 75 (85%) 19 (28%) ,0.0001
doi:10.1371/journal.pone.0021174.t001
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cytokines, including VEGF and bFGF, were not associated with
the presence or absence of collaterals in the best-fit model.
Determinants of the extent of collaterals
In order to determine whether chemokine levels are predictive
of the extent of collateralization, when present, we measured plasma
levels of the individual cytokines in patients with collaterals
(Rentrop score of 1 to 3) and without collaterals (Rentrop score of
0) (Table 4, p values represent differences among groups, one-way
ANOVA). Increasing Rentrop scores (representing more extensive
collateralization), were associated with increasing median plasma
levels of the angiogenic CXC chemokine, CXCL1 (p,0.0001 for
differences among groups, one-way ANOVA) (Table 4, Figure 1).
Increasing Rentrop scores were also associated with progressively
lower levels of the angiostatic CXC chemokines, CXCL9
(p,0.0001), CXCL10 (p=0.002), and CXCL11 (p=0.0002).
IFN-c is a potent inducer of the angiostatic chemokines CXCL9,
CXCL10, and CXCL11, and the levels of IFN-c were similarly
negatively correlated to the extent of coronary collaterals
(p=0.0004) (Table 4, Figure 2). In addition, we found that
CXCL12 (p=0.022), VEGF (p=0.008) and CCL2 (p=0.0002)
had a significant negative correlation across increasing Rentrop
scores (Table 4, Figure 2). There was no difference in the levels of
bFGF between patients with and without collaterals (Table 4,
Figure 2).
Discussion
In patients with chronic IHD, coronary collateralization
maintains myocardial viability in the collateral-fed distribution
[27] and is associated with fewer and smaller myocardial
infarctions [5], less ventricular aneurysm formation, better left
ventricular function, less arrhythmias and better survival com-
pared to those who do not recruit collaterals [2,12,13,14,28,29]. It
is recognized that patients with similar extent and severity of
coronary artery disease exhibit marked heterogeneity in the
presence and extent of angiographically detectable spontaneous
coronary collaterals; this heterogeneity is not explained by
traditional cardiac risk factors. Our multivariable model, which
includes clinical factors and cytokine levels, suggests that the
angiogenic and angiostatic CXC chemokines play an important
role in both the presence and extent of spontaneously visible
coronary collaterals.
Prior studies that examined the role of clinical factors on
coronary collateralization have yielded conflicting results: For
example, in some studies, diabetes mellitus was found to be a
negative predictor of the presence of collaterals [30,31,32,33,34],
while in others it was not [35,36,37,38,39]. In the present study,
we found a negative association between diabetes mellitus and
coronary collateralization and a positive association with hyper-
lipidemia, but independent of HMG-CoA reductase inhibitor
therapy as has been reported by others [40,41]. As expected, we
also found that patients who had at least one occluded coronary
artery were more likely to have collaterals than those who did not.
Substantial preclinical data have implicated growth factors as
critical mediators of collateral formation in animal models of
hind limb ischemia (reviewed in [42]). Based on this literature,
studies of mediators of vascular remodeling in humans have
primarily focused on the role of the growth factors VEGF
and bFGF in coronary collateralization in chronic IHD
[17,18,19,20,21,34,43,44]. With regard to the role of growth
factors as predictors of coronary collaterals, studies have been
Table 2. Univariate predictors of the presence of coronary
artery collaterals.
Variable Estimate (x10
4) p value
Angiogenic and angiostatic factors
Angiogenic
CXCL1 +0.022 0.428
CXCL3 +2.895 0.056
CXCL5 +0.406 0.041
CXCL8 +1.154 0.277
CXCL12 +0.579 0.169
CCL2 +5.445 0.246
VEGF* 20.385 0.604
bFGF{ +0.346 0.100
Angiostatic
CXCL9 +0.014 0.722
CXCL10 +0.137 0.618
CXCL11 21.350 0.027
IFN-c
{ 23.858 0.013
Clinical factors
Hypertension 22.275 0.006
Diabetes 21.017 0.053
Current tobacco use 20.418 0.431
Family history of coronary artery disease 20.214 0.666
Hyperlipidemia +2.087 0.032
Prior angina pectoris 20.566 0.259
Peripheral vascular disease +0.088 0.891
Congestive heart failure 20.522 0.586
History of cardiac arrhythmias 20.200 0.797
Prior myocardial infarction +0.727 0.165
Prior stroke 21.203 0.187
Prior percutaneous coronary intervention 20.841 0.120
Prior coronary artery bypass surgery 21.734 0.006
Presence of an occluded artery +4.302 ,0.0001
Number of diseased vessels 20.003 0.990
*VEGF= vascular endothelial growth factor, {bFGF= basic fibroblast growth
factor,
{IFN= interferon.
doi:10.1371/journal.pone.0021174.t002
Table 3. Best fit (multivariate) model for the presence of
coronary artery collaterals.
Variable Estimate (x10
4) p value
CXCL5 +0.609 0.018
CXCL8 +2.555 0.031
CXCL11 22.409 0.002
CXCL12 +1.389 0.033
IFN-gamma 23.833 0.021
Hyperlipidemia +1.924 0.047
Hypertension 22.431 0.007
Diabetes 21.729 0.004
Presence of an occluded artery +4.588 ,0.0001
IFN=interferon.
doi:10.1371/journal.pone.0021174.t003
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reporting a positive association between plasma growth factors
and the presence of collaterals. For instance, in a study with a
similar design to ours, plasma levels of VEGF, PDGF, bFGF, or
hepatocyte growth factor did not differ significantly between
patients with and without coronary collaterals [20]. Surpris-
ingly, we found that VEGF and bFGF levels were not
associated with the presence of collaterals; moreover, we found
Figure 1. Box plots (median and interquartile range) of percentile rank of plasma concentrations of cytokines that promote
vascular remodeling: CXCL1 (panel A), CXCL3 (panel B), CXCL5 (panel C), CXCL8 (panel D), CXCL12 (panel E), CCL2 (panel F), VEGF
(panel G), and bFGF (panel H). CXCL1 (*p,0.0001), CXCL12 (*p=0.0022), CCL2 (*p=0.0002), and VEGF (*p=0.008) significantly
correlated across increasing Rentrop scores.
doi:10.1371/journal.pone.0021174.g001
Table 4. Plasma levels of angiogenic and angiostatic factors according to collateralization.
Rentrop 0
(n=68)
Rentrop 1
(n=28)
Rentrop 2
(n=34)
Rentrop 3
(n=26) p value
Median
pg/ml IQR
1
Median
pg/ml IQR
1
Median
pg/ml IQR
1
Median
pg/ml IQR
1
Angiogenic
CXCL1 6358 1674–0017 2798 1386–7429 6702 1276–15147 24966 10206–138085 ,0.0001
CXCL3 667 235–1503 1045 679–1950 960 345–1394 876 381–1384 0.278
CXCL5 6542 4538–9431 7821 4251–13609 8517 5058–14425 9247 5081–21997 0.272
CXCL8 1120 468–2722 2095 759–3642 1190 679–2212 1024 420–2845 0.398
CXCL12 2234 1888–10176 9989 2234–11274 2353 2043–9640 2107 1991–3099 0.022
CCL2 80 40–168 152 83–486 90 22–156 39 27–95 0.0002
VEGF* 1565 660–2579 1947 1266–3710 1428 262–2450 761 0–1700 0.008
bFGF{ 0 0–1170 0 0–10990 0 0–4177 52 0–4820 0.555
Angiostatic
CXCL9 4905 1005–22397 17381 8951–37874 5394 848–9150 392 0–3019 ,0.0001
CXCL10 1375 737–2251 1664 1324–3692 1232 795–1967 722 580–2008 0.002
CXCL11 6085 3568–9169 7710 5664–11733 5349 3252–8558 3155 2455–6011 0.0002
IFN-c
{ 311 147–565 552 371–1204 290 154–512 189 92–431 0.0004
*VEGF= vascular endothelial growth factor, {bFGF= basic fibroblast growth factor,
{IFN= interferon,
1IQR=inter-quartile range.
doi:10.1371/journal.pone.0021174.t004
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the extent of collateralization when present.
The role of chemokines in mediating vascular remodeling has
been extensively documented in diverse biological settings, with
the notable exception of revascularization of ischemic myocardi-
um. In one study using a canine model of ischemia/reperfusion
injury, investigators showed that short periods of ischemia/
reperfusion that were not sufficient to produce a myocardial
infarction resulted in increased expression of CCL2 mRNA in the
ischemic myocardium suggesting a potential role in angiogenesis
[45]. Investigators have reported the over-expression of CXCL8 in
atherectomy samples from human coronary artery plaque [46].
Others have shown myocardial chemokine and chemokine
receptor expression in human end-stage heart failure [47], but
their specific contribution to vascular remodeling has not been
established. While these studies primarily concentrated on specific
chemokines such as CCL2 and CXCL8, we present data on a
complete panel of angiogenic and angiostatic chemokines. Lastly,
in a previous clinical study, a predictive model incorporating
plasma chemokine levels identified individuals with clinically
significant coronary artery disease with better resolution than
traditional cardiac risk factors [48]. However, this study did not
address the issue of collaterals and the model did not include
angiogenic CXC chemokine ligands.
Interestingly, angiogenic and angiostatic factors associated
with the presence or absence of collaterals were not found to be
necessarily associated with the extent of collateralization in our
dataset: for example, CXCL5, CXCL8, CXCL11, CXCL12,
and IFN-c added significant independent information about the
presence or absence of collaterals (Table 3), while CXCL1,
CCL2, CXCL9, and CXCL10 added information regarding the
extent of collateralization (Table 4, Figures 1 and 2). We
interpret this finding as follows: local myocardial ischemia may
serve as a stimulus for angiogenic chemokine secretion and
collateral recruitment. As the collateral is successfully recruited,
the ischemic stimulus is no longer operational, resulting in
downregulation of the angiogenic ligand. Our model suggests
that while arterial occlusion, but not extent of coronary artery
disease, is an important first step in recruiting collaterals, their
subsequent development is affected by circulating chemokine
levels.
Limitations
Our study has several limitations. First, we may have
underestimated the presence of collaterals by measuring only
spontaneously visible coronary collaterals [14,15,18,28,29]. Sec-
ond, due to the relatively small number of patients, our study may
be under-powered to detect significant differences in baseline
demographics between the two groups. Third, it is possible that
there were differences in factors we did not collect, including the
chronicity of angina and participation in a regular exercise
program. Fourth, the measurement of CXC chemokines in
plasma may be subject to methodological and biological varia-
bility. However, we minimized such variability by collecting the
samples before the first administration of heparin, and by rapidly
cooling and processing the samples. The plasma samples were
frozen at 280uC in multiple aliquots from each patient, and all
measurements were taken on samples that had been thawed only
once. Biological variability was also minimized since all our
patients were fasting and at steady-state prior to angiography.
Although we did not enroll patients with known unstable angina or
myocardial infarction, it is possible that recent symptoms in the
peri-catheterization period that were not captured on our history
could have affected our results. Nonetheless, since the plasma half-
lives of chemokine ligands are short (,2 hrs), plasma levels are
more likely representative of on-going myocardial ischemia than
remote events. Finally and most importantly, our results reflect an
association but do not establish a causal relationship between the
presence and extent of coronary artery collaterals and levels of
circulating chemokines, which is not possible in a human system.
The biological basis for the heterogeneity in coronary
collateralization in patients with chronic IHD has not been
established and is important to patient outcomes. Our findings
indicate that an occluded coronary artery is highly correlated with
the presence of a spontaneously visible collateral, and plasma
concentrations of angiogenic and angiostatic chemokines (but not
growth factors) add significant independent information regarding
the presence and extent of collaterals, supporting the hypothesis
that these molecules are associated with recruitment of coronary
collaterals to the chronically ischemic myocardium.
The present work has two potential implications: first, it
provides insight into a plausible biological mechanism that
underlies the clinically observed heterogeneity in the degree of
spontaneously visible coronary collateralization in patients with
chronic IHD. If future studies identify angiogenic and angiostatic
chemokines as mediating collateral recruitment in this population,
this may translate into potential therapeutic options. Second, the
present study shows that a statistical model can identify the
presence and extent of spontaneous collaterals in a cross-sectional
analysis. If this model is found to identify IHD patients destined to
recruit collaterals in future longitudinal studies, it may impact the
management of this common illness. Lastly, the mechanism(s)
behind the selective increase in angiogenic chemokines accompa-
nied by a reduction in IFN-gamma inducible angiostatic CXC
chemokines seen in our study is unknown and warrants further
study including the possibility of genetic variation.
Acknowledgments
Cynthia Scott-Simms, R.N. for help in subject recruitment and collection
of samples.
Figure 2. Box plots (median and interquartile range) of
percentile rank of plasma concentrations of cytokines that
inhibit vascular remodeling: CXCL9 (panel A), CXCL10 (panel B),
CXCL11 (panel C), and IFN-c (panel D). All cytokines significantly
correlated across increasing Rentrop scores: CXCL9 (*p,0.0001),
CXCL10 (*p=0.002), CXCL11 (*p=0.0002), and IFN-c (*p=0.0004).
doi:10.1371/journal.pone.0021174.g002
Chemokines and Coronary Collaterals
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21174Author Contributions
Conceived and designed the experiments: ECK BM RMS JRM.
Performed the experiments: ECK JRM LL BM LWG LCL MR AMT
DEL MDB RMS. Analyzed the data: ECK BM DEL MDB JRM.
Contributed reagents/materials/analysis tools: DEL BM RMS JRM ECK.
Wrote the paper: ECK BM RMS JRM.
References
1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, et al. (2008) Heart
disease and stroke statistics–008 update: a report from the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee. Circula-
tion 117: e25–146.
2. Regieli JJ, Jukema JW, Nathoe HM, Zwinderman AH, Ng S, et al. (2009)
Coronary collaterals improve prognosis in patients with ischemic heart disease.
Int J Cardiol 132: 257–262.
3. Hirai T, Fujita M, Nakajima H, Asanoi H, Yamanishi K, et al. (1989)
Importance of collateral circulation for prevention of left ventricular aneurysm
formation in acute myocardial infarction. Circulation 79: 791–796.
4. Kodama K, Kusuoka H, Sakai A, Adachi T, Hasegawa S, et al. (1996) Collateral
channels that develop after an acute myocardial infarction prevent subsequent
left ventricular dilation. J Am Coll Cardiol 27: 1133–1139.
5. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, et al. (1991) Influence
of coronary collateral vessels on myocardial infarct size in humans. Results of
phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI
Investigators. Circulation 83: 739–746.
6. Elsman P, van ’t Hof AW, de Boer MJ, Hoorntje JC, Suryapranata H, et al.
(2004) Role of collateral circulation in the acute phase of ST-segment-elevation
myocardial infarction treated with primary coronary intervention. Eur Heart J
25: 854–858.
7. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, et al. (2005)
Comparison of the cardioprotective effect of prodromal angina pectoris and
collateral circulation in patients with a first anterior wall acute myocardial
infarction. Am J Cardiol 95: 622–625.
8. Desch S, de Waha S, Eitel I, Koch A, Gutberlet M, et al. (2010) Effect of coronary
collaterals on long-term prognosis in patients undergoing primary angioplasty
for acute ST-elevation myocardial infarction. Am J Cardiol 106: 605–611.
9. Koerselman J, de Jaegere PP, Verhaar MC, Grobbee DE, van der Graaf Y
(2005) Prognostic significance of coronary collaterals in patients with coronary
heart disease having percutaneous transluminal coronary angioplasty.
Am J Cardiol 96: 390–394.
10. Abbott JD, Choi EJ, Selzer F, Srinivas VS, Williams DO (2005) Impact of
coronary collaterals on outcome following percutaneous coronary intervention
(from the National Heart, Lung, and Blood Institute Dynamic Registry).
Am J Cardiol 96: 676–680.
11. Nathoe HM, Buskens E, Jansen EW, Suyker WJ, Stella PR, et al. (2004) Role of
coronary collaterals in off-pump and on-pump coronary bypass surgery.
Circulation 110: 1738–1742.
12. Nathoe HM, Koerselman J, Buskens E, van Dijk D, Stella PR, et al. (2006)
Determinants and prognostic significance of collaterals in patients undergoing
coronary revascularization. Am J Cardiol 98: 31–35.
13. Caputo M, Anis RR, Rogers CA, Ahmad N, Rizvi SI, et al. (2008) Coronary
collateral circulation: effect on early and midterm outcomes after off-pump
coronary artery bypass surgery. Ann Thorac Surg 85: 71–79.
14. Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, et al. (2002)
Physiologically assessed coronary collateral flow and adverse cardiac ischemic
events: a follow-up study in 403 patients with coronary artery disease. J Am Coll
Cardiol 40: 1545–1550.
15. Seiler C (2010) The human coronary collateral circulation. Eur J Clin Invest 40:
465–476.
16. Koerselman J, van der Graaf Y, de Jaegere PP, Grobbee DE (2003) Coronary
collaterals: an important and underexposed aspect of coronary artery disease.
Circulation 107: 2507–2511.
17. Briguori C, Testa U, Colombo A, Petrucci E, Condorelli G, et al. (2006)
Relation of various plasma growth factor levels in patients with stable angina
pectoris and total occlusion of a coronary artery to the degree of coronary
collaterals. Am J Cardiol 97: 472–476.
18. Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, et al. (1999)
Physiologically assessed coronary collateral flow and intracoronary growth factor
concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation
100: 1945–1950.
19. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, et al. (2004)
Reduced pericardial levels of endostatin correlate with collateral development in
patients with ischemic heart disease. J Am Coll Cardiol 43: 1383–1387.
20. Sherman JA, Hall A, Malenka DJ, De Muinck ED, Simons M (2006) Humoral
and cellular factors responsible for coronary collateral formation. Am J Cardiol
98: 1194–1197.
21. Werner GS, Jandt E, Krack A, Schwarz G, Mutschke O, et al. (2004) Growth
factors in the collateral circulation of chronic total coronary occlusions: relation
to duration of occlusion and collateral function. Circulation 110: 1940–1945.
22. Keeley EC, Mehrad B, Strieter RM (2008) Chemokines as mediators of
neovascularization. Arterioscler Thromb Vasc Biol 28: 1928–1936.
23. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, et al. (1995)
The functional role of the ELR motif in CXC chemokine-mediated
angiogenesis. J Biol Chem 270: 27348–27357.
24. Levin DC (1974) Pathways and functional significance of the coronary collateral
circulation. Circulation 50: 831–837.
25. Rentrop KP, Cohen M, Blanke H, Phillips RA (1985) Changes in collateral
channel filling immediately after controlled coronary artery occlusion by an
angioplasty balloon in human subjects. J Am Coll Cardiol 5: 587–592.
26. van Liebergen RA, Piek JJ, Koch KT, de Winter RJ, Schotborgh CE, et al.
(1999) Quantification of collateral flow in humans: a comparison of
angiographic, electrocardiographic and hemodynamic variables. J Am Coll
Cardiol 33: 670–677.
27. Piek JJ, van Liebergen RA, Koch KT, Peters RJ, David GK (1997) Clinical,
angiographic and hemodynamic predictors of recruitable collateral flow assessed
during balloon angioplasty coronary occlusion. J Am Coll Cardiol 29: 275–282.
28. Berry C, Balachandran KP, L’Allier PL, Lesperance J, Bonan R, et al. (2007)
Importance of collateral circulation in coronary heart disease. Eur Heart J 28:
278–291.
29. Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, et al. (2007) Beneficial
effect of recruitable collaterals: a 10-year follow-up study in patients with stable
coronary artery disease undergoing quantitative collateral measurements.
Circulation 116: 975–983.
30. A b a c iA ,O g u z h a nA ,K a h r am a nS ,Er y o lN K ,U n a lS ,eta l .( 1 99 9 )E f f e c to fd i ab et es
mellitus on formation of coronary collateral vessels. Circulation 99: 2239–2242.
31. Kornowski R (2003) Collateral formation and clinical variables in obstructive
coronary artery disease: the influence of hypercholesterolemia and diabetes
mellitus. Coron Artery Dis 14: 61–64.
32. Nisanci Y, Sezer M, Umman B, Yilmaz E, Mercanoglu S, et al. (2002)
Relationship between pressure-derived collateral blood flow and diabetes
mellitus in patients with stable angina pectoris: a study based on coronary
pressure measurement. J Invasive Cardiol 14: 118–122.
33. Nurkalem Z, Gorgulu S, Uslu N, Alper AT, Orhan AL, et al. (2008) Effect of
glucometabolic disorders on the formation of coronary collaterals in occlusive
coronary artery disease. Acta Cardiol 63: 141–146.
34. Waltenberger J (2001) Impaired collateral vessel development in diabetes: potential
cellular mechanisms and therapeutic implications. Cardiovasc Res 49: 554–560.
35. Cohen M, Sherman W, Rentrop KP, Gorlin R (1989) Determinants of collateral
filling observed during sudden controlled coronary artery occlusion in human
subjects. J Am Coll Cardiol 13: 297–303.
36. Mason MJ, Walker SK, Patel DJ, Paul VE, Ilsley CD (2000) Influence of clinical
and angiographic factors on development of collateral channels. Coron Artery
Dis 11: 573–578.
37. Olijhoek JK, Koerselman J, de Jaegere PP, Verhaar MC, Grobbee DE, et al.
(2005) Presence of the metabolic syndrome does not impair coronary collateral
vessel formation in patients with documented coronary artery disease. Diabetes
Care 28: 683–689.
38. Pohl T, Seiler C, Billinger M, Herren E, Wustmann K, et al. (2001) Frequency
distribution of collateral flow and factors influencing collateral channel
development. Functional collateral channel measurement in 450 patients with
coronary artery disease. J Am Coll Cardiol 38: 1872–1878.
39. Zbinden R, Zbinden S, Billinger M, Windecker S, Meier B, et al. (2005)
Influence of diabetes mellitus on coronary collateral flow: an answer to an old
controversy. Heart 91: 1289–1293.
40. Dincer I, Ongun A, Turhan S, Ozdol C, Kumbasar D, et al. (2006) Association
between the dosage and duration of statin treatment with coronary collateral
development. Coron Artery Dis 17: 561–565.
41. Pourati I, Kimmelstiel C, Rand W, Karas RH (2003) Statin use is associated
with enhanced collateralization of severely diseased coronary arteries. Am
Heart J 146: 876–881.
42. Hughes GC, Annex BH (2005) Angiogenic therapy for coronary artery and
peripheral arterial disease. Expert Rev Cardiovasc Ther 3: 521–535.
43. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, et al. (2003)
Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic
severity of coronary artery disease. Heart 89: 1411–1415.
44. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, et al. (1999) Interindividual
heterogeneity in the hypoxic regulation of VEGF: significanceforthe development
of the coronary artery collateral circulation. Circulation 100: 547–552.
45. Lakshminarayanan V, Lewallen M, Frangogiannis NG, Evans AJ, Wedin KE,
et al. (2001) Reactive oxygen intermediates induce monocyte chemotactic
protein-1 in vascular endothelium after brief ischemia. Am J Pathol 159:
1301–1311.
4 6 . S i m o n i n iA ,M o s c u c c iM ,M u l l e rD W ,B a t e sE R ,P a g a n iF D ,e ta l .( 2 0 0 0 )I L - 8i sa n
angiogenicfactorinhumancoronaryatherectomytissue.Circulation101:1519–1526.
47. Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, et al. (2000) Myocardial
expression of CC- and CXC-chemokines and their receptors in human end-
stage heart failure. Cardiovasc Res 47: 778–787.
48. Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, et al. (2007) Circulating
chemokines accurately identify individuals with clinically significant atheroscle-
rotic heart disease. Physiol Genomics 31: 402–409.
Chemokines and Coronary Collaterals
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21174